BIOA
BioAge Labs, Inc. Common StockBIOA
BIOA
About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Employees: 64
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
23% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 30
12% more funds holding
Funds holding: 57 [Q3] → 64 (+7) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
29% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]
74% less capital invested
Capital invested by funds: $434M [Q3] → $114M (-$320M) [Q4]
1158.57% less ownership
Funds ownership: 1213.35% [Q3] → 54.78% (-1158.57%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
43%
upside
Avg. target
$5
43%
upside
High target
$5
43%
upside
2 analyst ratings
0 positive
0%
1 neutral
50%
1 negative
50%
Citigroup Samantha Semenkow 0 / 0 met price target | 43%upside $5 | Neutral Maintained | 24 Mar 2025 |
Morgan Stanley Jeffrey Hung 19% 1-year accuracy 5 / 27 met price target | 43%upside $5 | Underweight Assumed | 7 Mar 2025 |
Financial journalist opinion
Based on 109 articles about BIOA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended December 31, 2024.
Neutral
Accesswire
3 weeks ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. Lawsuit - BIOA
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135139&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
3 weeks ago
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
LOS ANGELES , March 10, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the federal securities laws. Shareholders who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.
Neutral
Accesswire
3 weeks ago
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BIOA
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135128&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
3 weeks ago
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
NEW YORK , March 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024 (the "IPO"), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
3 weeks ago
Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135100&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
3 weeks ago
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public offering conducted on September 26, 2024 (the “IPO”), of the important March 10, 2025 lead plaintiff deadline.
Neutral
Business Wire
3 weeks ago
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Neutral
Accesswire
3 weeks ago
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIOA
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135084&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 weeks ago
Investors Who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135031&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™